drugset / Trial / NCT05338541

Tucidinostat Plus Etoposide in the Treatment of Neuroblastoma in Childhood.

NCT05338541

Phase 1 Unknown 30 enrolled Yizhuo Zhang
NaSingle-groupOpen-labelTreatment

Summary

Neuroblastoma is a malignant tumor that develops in infants and kids. Dysregulation of histone acetylation is associated with a series of malignant tumors. Neuroblastoma is caused by defective neural crest differentiation due to abnormal gene regulation.

Timeline

Start
2022-05-27
Primary completion
2024-06-30
Completion
2024-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Etoposide Small molecule 50 mg/m2
Subject Tucidinostat Small molecule 14 mg/m2
Subject Tucidinostat Small molecule 17.5 mg/m2
Subject Tucidinostat Small molecule 23 mg/m2

Indications